Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis

5α-reductase inhibitors (5-ARI) are widely employed for the treatment of benign prostatic hyperplasia. It has been noted that 5-ARI exhibit the potential to attenuate the risk of prostate cancer, but consistent agreement has not been achieved. Moreover, the effect of 5-ARI on cancer-specific mortali...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Lian-Min, Yang, Re-Dian, Wang, Jia-Min, Zhao, Shan-Kun, Liu, Yang-Zhou, Zhu, Zhi-Guo, Xiang, Qian, Zhao, Zhi-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523616/
https://www.ncbi.nlm.nih.gov/pubmed/31710001
http://dx.doi.org/10.4103/aja.aja_112_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523616/
https://www.ncbi.nlm.nih.gov/pubmed/31710001
http://dx.doi.org/10.4103/aja.aja_112_19

Ejemplares similares